Right, Tesamorelin's a type one
GLP-1 indeed stimulates postprandial insulin secretion, inhibits glucagon release, and reduces food intake through the delay of gastric emptying and the suppression of appetite (59)
Front Surg 10:1157661 Roth JS, Anthone GJ, Selzer DJ, Poulose BK, Pierce RA, Bittner JG, Hope WW, Dunn RM, Martindale RG, Goldblatt MI, Earle DB, Romanelli JR, Mancini GJ, Greenberg JA, Linn JG, Parra-Davila E, Sandler BJ, Deeken CR, Badhwar A, Salluzzo JL, Voeller GR (2022) Long-term, prospective, multicenter study of poly-4-hydroxybutyrate mesh (Phasix mesh) for hernia repair in cohort at risk for complication: 60-month follow-up
Bottom line Skin, hair and nail changes are among the most common appearance-related concerns people report while taking GLP-1 medications
The recombinant human GLP-1(7-36) [RhGLP-1 (7-36)], a biosynthetic agent belonging to the GLP-1 RAs, is also applied to treat T2DM clinically
Wierenga, K